Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT03254667
Enrolling by invitation Observational

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

NCT03254667 · tracked via the Priya Life Science USA tracker
Sponsor
Bausch Health Americas, Inc
Phase
Observational
Started
2017-07-25
Last updated
2025-09-16

Condition(s) studied

Psoriasis

Investigational drug(s) / intervention(s)

Brodalumab →Comparator Drug (non-biologic IL-17 inhibitors)

Brodalumab: Brodalumab

Comparator Drug (non-biologic IL-17 inhibitors): Comparator subjects treated with non-biologic IL-17 inhibitors

Study summary

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: 1. Diagnosis and main criteria for inclusion: a subject must have moderate to severe psoriasis diagnosed by a dermatologist 2. Must be at least 18 years of age or older 3. Started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments and select non-biologic treatments (eg, methotrexate, cyclosporine, or apremilast only) are permitted. Exclusion Criteria: 1. The subject is unable or unwilling to provide informed consent to participate in the registry. 2. The subject is participating or planning to participate in a clinical trial with a non-marketed or marketed investigational drug (i.e. Phase I-IV drug trial). 3. The subject is restarting the eligible medication less than 12 months since receiving the last dose.

Primary outcome measure(s)

  • Assess the incidence of malignancy — 8 years
    Assess the incidence of malignancy, excluding non-melanoma skin cancer (NMSC), in adult psoriasis subjects exposed to brodalumab in the course of actual clinical care compared to non-IL-17-inhibitor biologic medications used to treat psoriasis.

Trial sites (1)

FacilityCityRegionStatus
Registry Bridgewater New Jersey

On this site

📄 Siliq (brodalumab) drug profile →

More Bausch Health Americas, Inc. trials in the USA

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Recruiting
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects Active, not recruiting
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment Recruiting
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) Recruiting
A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing Active, not recruiting

Other trials for the same condition

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques Recruiting
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects Active, not recruiting
A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis Recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Active, not recruiting
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03254667 on ClinicalTrials.gov ↗ ← All trials in the USA